These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

871 related items for PubMed ID: 27081177

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
    Gueneau P, Chretien ML, Cransac-Miet A, Aho LS, Lafon I, Favennec C, Guy J, Caillot D, Boulin M.
    Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
    [Abstract] [Full Text] [Related]

  • 24. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG.
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [Abstract] [Full Text] [Related]

  • 25. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
    Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.
    Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
    [Abstract] [Full Text] [Related]

  • 26. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
    Scott LJ.
    Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
    [Abstract] [Full Text] [Related]

  • 27. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
    Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC.
    Haematologica; 2024 Jul 01; 109(7):2239-2249. PubMed ID: 38299578
    [Abstract] [Full Text] [Related]

  • 28. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
    Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T, Intergroupe Francophone du Myélome.
    Blood; 2013 Mar 14; 121(11):1968-75. PubMed ID: 23319574
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S.
    Cancer; 2019 Sep 01; 125(17):2991-3000. PubMed ID: 31090928
    [Abstract] [Full Text] [Related]

  • 31. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
    Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J.
    Eur J Haematol; 2017 Sep 01; 99(3):199-206. PubMed ID: 28504846
    [Abstract] [Full Text] [Related]

  • 32. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H.
    Ann Hematol; 2011 Apr 01; 90(4):429-39. PubMed ID: 20857112
    [Abstract] [Full Text] [Related]

  • 33. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
    Li Y, Kassir N, Wang X, Palmisano M, Zhou S.
    J Clin Pharmacol; 2020 Aug 01; 60(8):1061-1075. PubMed ID: 32168381
    [Abstract] [Full Text] [Related]

  • 34. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
    Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM.
    Cancer; 2010 Aug 15; 116(16):3807-14. PubMed ID: 20564094
    [Abstract] [Full Text] [Related]

  • 35. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R.
    Blood Adv; 2019 Feb 26; 3(4):603-611. PubMed ID: 30792190
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
    Matsue K, Iwasaki H, Chou T, Tobinai K, Sunami K, Ogawa Y, Kurihara M, Midorikawa S, Zaki M, Doerr T, Iida S.
    Cancer Sci; 2015 Nov 26; 106(11):1561-7. PubMed ID: 26292221
    [Abstract] [Full Text] [Related]

  • 38. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
    Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R, Grote L, Peluso T, Dimopoulos M.
    Eur J Haematol; 2022 Jan 26; 108(1):73-83. PubMed ID: 34496096
    [Abstract] [Full Text] [Related]

  • 39. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R.
    Clin Lymphoma Myeloma Leuk; 2019 Sep 26; 19(9):570-578.e1. PubMed ID: 31326409
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.